Resistin in rodents and humans

Area of Science:

• Endocrinology
• Metabolic Syndrome
• Cardiovascular Biology

Background:

• Obesity involves excess lipid accumulation and chronic inflammation, contributing to insulin resistance and type 2 diabetes.
• Resistin, initially identified as an adipose-secreted hormone in rodents, is linked to obesity and insulin resistance.
• In humans, resistin is primarily expressed by macrophages and elevated in inflammatory states, with potential links to insulin resistance, diabetes, and cardiovascular disease.

Purpose of the Study:

• To review the biology of resistin in both rodents and humans.
• To examine the evidence connecting resistin to type 2 diabetes, atherosclerosis, and cardiovascular disease.

Main Methods:

• Literature review focusing on resistin's role in metabolic and cardiovascular diseases.
• Analysis of studies investigating resistin expression, function, and clinical associations.

Main Results:

• Rodent studies show resistin from adipose tissue is linked to insulin resistance.
• Human studies indicate macrophage-derived resistin increases with inflammation and is associated with insulin resistance, diabetes, and cardiovascular issues.
• Resistin promotes atherosclerosis through endothelial dysfunction, vascular smooth muscle cell proliferation, inflammation, and foam cell formation, and predicts poor outcomes in cardiovascular disease patients.

Conclusions:

• Resistin is implicated in the pathogenesis of atherosclerosis and heart failure.
• Further understanding of resistin's role is crucial for managing obesity-related metabolic and cardiovascular complications.